No Data
No Data
Zhixiang Jintai (688443.SH): Chairman of the board, Shan Jikuan, proposes to repurchase company shares.
On September 13, Gelonhui announced that on September 13, 2024, the company received a letter from Mr. Shan Jikuan, the chairman of the company, proposing the repurchase of the company's shares by Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. The repurchased shares will be used for stock-based incentives, employee shareholding plans, or other purposes, with a total repurchase amount not less than RMB 20 million (including principal) and not more than RMB 40 million (including principal), subject to the specific repurchase share plan approved by the board of directors.
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Zhixiang Jintai (688443.SH) released its performance for the first half of the year, with a net loss of 0.362 billion yuan.
Zhixiang Jintai (688443.SH) released the 2024 interim report, with a revenue of 1...
Genrix Biopharmaceutical's Celecoxib Injection Gets Nod to Be Registered; Shares Drop 4%
The first approved product on the market, Zhixiang Jintai (688443.SH): Celgene's monoclonal antibody for the treatment of moderate to severe plaque psoriasis.
Zhixiang Jintai (688443.SH) announced today that the company has received the "Pharmaceuticals..." issued by the State Administration for Market Regulation.
No Data
No Data